Back to search

Article

Tislelizumab in combination with gemcitabine plus cisplatin chemotherapy as first-line adjuvant treatment for locally advanced or metastatic bladder cancer: a retrospective study

2022-05-16

Abstract excerpt

<title>Abstract</title> <p><bold>Background:</bold> Combining immune checkpoint inhibitors (ICIs) with chemotherapy can synergistically improve antitumor activity and are generally well tolerated.<italic> </italic>Recently, the efficacy and safety of combination therapy has been demonstrated for many cancers, including urothelial carcinomas. The aim of this retrospective pilot study was to evaluate the efficacy a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
428baf22-6718-58b5-97b7-45f54409074d
DOI
10.21203/rs.3.rs-1600863/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Tislelizumab in combination with gemcitabine plus cisplatin chemotherapy as first-line adjuvant treatment for locally advanced or metastatic bladder cancer: a retrospective studyDOI 10.21203/rs.3.rs-1600863/v1
Real-World Outcomes of Second-Line Pembrolizumab in Urothelial Carcinoma: A Multicenter Analysis from the Campania Oncological Network (ROC)Semantic proximity
A Muscle-Invasive Bladder Cancer Patient With High Tumor Mutational Burden and RB1 Mutation Achieved Bladder Preservation Following Chemotherapy Combined With Immunotherapy: A Case Report.Semantic proximity
Immunotherapy in Bladder Cancer: A Systematic Review of Clinical Trials and Therapeutic AdvancesSemantic proximity
A retrospective study of tislelizumab combined with chemotherapy for downstaging and conversion therapy in patients with locally advanced lung cancerSemantic proximity
The Efficacy and Safety of Pembrolizumab, Ipilimumab, and Nivolumab Monoteraphy and Combination for Colorectal Cancer: A Systematic Review and Meta-AnalysisSemantic proximity
Gemcitabine plus Oxaliplatin (GEMOX) combined with Atezolizumab and Bevacizumab for Advanced Biliary Tract Cancer: A Preliminary Observational StudySemantic proximity
Immune Checkpoint Inhibitor Resistance in Genitourinary Cancers: Mechanisms, Biomarkers, and Emerging Therapeutic StrategiesSemantic proximity
Study Protocol of A Phase II Study to Evaluate Safety and Efficacy of Neo-adjuvant Pembrolizumab and Radiotherapy in Localized Rectal CancerSemantic proximity
Tislelizumab in previously treated, locally advanced unresectable/metastatic microsatellite instability-high/mismatch repair-deficient solid tumorsSemantic proximity
Optimal immunotherapy regimens for NSCLC patients with KRAS mutations: a systematic review and network meta-analysisSemantic proximity
Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes.Semantic proximity
Chemotherapy and targeted therapy for advanced biliary tract cancers：An umbrella reviewSemantic proximity
Select a neighboring publication to make it the new centre.